Compare RNST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | EVO |
|---|---|---|
| Founded | 1904 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | RNST | EVO |
|---|---|---|
| Price | $36.58 | $3.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.33 | $7.00 |
| AVG Volume (30 Days) | ★ 546.4K | 250.0K |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | $775,309,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $43.37 | N/A |
| Revenue Next Year | $13.13 | $8.52 |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $26.97 | $2.84 |
| 52 Week High | $40.40 | $4.80 |
| Indicator | RNST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 71.81 |
| Support Level | $35.32 | $3.10 |
| Resistance Level | $36.47 | $3.23 |
| Average True Range (ATR) | 0.71 | 0.08 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 65.49 | 99.38 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.